Transmembrane potentials during high voltage shocks in ischemic cardiac tissue.
Transmembrane, voltage sensitive fluorescent dye (TMF) recording techniques have shown that high voltage shocks (HVS), typically used in defibrillation, produce either hyper- or depolarization of the transmembrane potential (TMP) when delivered in the refractory period of an action potential (AP) in normal cardiac tissue (NT). Further, HVS produce an extension of the AP, which has been hypothesized as a potential mechanism for electrical defibrillation. We examined whether HVS modify TMP of ischemic tissue (IT) in a similar manner. In seven Langendorff rabbit hearts, recordings of APs were obtained in both NT and IT with TMF using di-4-ANEPPS, and diacetylmonoxime (23 microM) to avoid motion artifacts. Local ischemia was produced by occlusion of the LAD, HVS of either biphasic (5 + 5 ms) or (3 + 2 ms) or monophasic shapes (5 ms) were delivered at varying times (20%-90%) of the paced AP. Intracardiac ECG and TMF recordings of the TMP were each amplified, recorded, and digitized at a frequency of 1 kHz. The paced AP in IT was triangular in shape with no obvious phase 3 plateau, typically seen in NT. There was normally a reduced AP amplitude (expressed as fractional fluorescence) in IT (2.6% +/- 1.79%) compared to 3.8% +/- 0.66% in NT, and shortened AP duration (137 +/- 42 vs 171 +/- 11 ms). One hundred-Volt HVS delivered during the refractory period of paced AP in IT in five rabbits, elicited a depolarization response of the TMP with an amplitude up to three times greater than the paced AP. This is in contrast to NT where the 100-V HVS produced hyperpolarization in four hearts, and only a slight depolarization response in one heart. These results suggest that HVS, typically delivered by a defibrillation shock, modify TMPs in a significantly different manner for ischemic cells, which may influence success in defibrillation.
Holley
L K
LK
Centre for Biomedical Technology, University of Technology Sydney, New South Wales, Australia.
Knisley
S B
SB
D000200:Action Potentials / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D002304:Cardiac Pacing, Artificial; D002863:Chromogenic Compounds; D003931:Diacetyl / Q000031:analogs & derivatives; D004554:Electric Countershock; D004562:Electrocardiography; D005260:Female; D005456:Fluorescent Dyes; D006321:Heart / Q000033:anatomy & histology / Q000502:physiology; D008297:Male; D008564:Membrane Potentials / Q000502:physiology*; D017202:Myocardial Ischemia / Q000473:pathology / Q000503:physiopathology*; D009991:Oscillometry; D011726:Pyridinium Compounds; D011817:Rabbits; D012032:Refractory Period, Electrophysiological / Q000502:physiology; D012044:Regression Analysis; D012815:Signal Processing, Computer-Assisted
D002863:Chromogenic Compounds; D005456:Fluorescent Dyes; D011726:Pyridinium Compounds; C004717:diacetylmonoxime; C050019:1-(3-sulfonatopropyl)-4-(beta)(2-(di-n-butylamino)-6-naphthylvinyl)pyridinium betaine; D003931:Diacetyl